Beryllium Disease Claims
BERYLLIUM DISEASE CLAIMS
Chronic Beryllium Disease (CBD) is a chronic, allergic-type lung response and chronic lung disease caused by exposure to beryllium and its compounds. Sometimes this disease is also called Berylliosis. A beryllium lymphocyte proliferation or transformation test (BeLPT/BeLTT) is a blood test that can tell if someone is sensitive or allergic to beryllium. Not everyone who tests positive for beryllium allergic reaction develops CBD. However, everyone who tests positive for the disease is allergic to beryllium. CBD is the body’s allergic response to beryllium exposure. The allergy usually comes from the lungs.
Under Part B of the Energy Employees Occupational Illness Compensation Program Act (EEOICPA), anyone who receives a CBD diagnosis can qualify for a $150,000 monetary compensation and free lifetime medical care. People who submit claims must include a proof of illness and work history. Part E impairment and wage loss is also available.
Part B has two sets of criteria that must be met to qualify for a claim. The BeLPT/BeLTT test did not exist before 1993, so there are pre-1993 and post-1993 qualification standards.
- Earliest dated document before 1993 that shows evidence of a chronic respiratory process
- Medical documentation showing at least three of the following:
- Abnormal chest x-ray
- Restrictive lung physiology testing
- Lung pathology consistent with CBD
- Clinical course consistent with a chronic respiratory disorder
- Positive test(s) that show beryllium sensitivity
- Earliest dated document after 1993
- Medical documentation showing both of the following:
- Positive BeLPT/BeLTT
Evidence of lung pathology consistent with CBD to include one of the following:
- Lung biopsy showing granulomas or lymphocytic process consistent with CBD
- CT scan showing changes consistent with CBD
- Pulmonary function tests showing results consistent with CBD
A diagnosis of Beryllium Sensitivity without CBD is possible when a claimant tests positive for the BeLPT/BeLTT but does not have CBD. In that case, the EEOICPA program does not provide financial compensation. Claimants can, however, periodically submit to testing for CBD. The expense of this test is covered by the EEOICPA.
If you have questions, contact the CWP Help Center at (888) 903-8989.